Alaa Hamed

987 total citations
44 papers, 616 citations indexed

About

Alaa Hamed is a scholar working on Physiology, Rheumatology and Psychiatry and Mental health. According to data from OpenAlex, Alaa Hamed has authored 44 papers receiving a total of 616 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Physiology, 14 papers in Rheumatology and 13 papers in Psychiatry and Mental health. Recurrent topics in Alaa Hamed's work include Lysosomal Storage Disorders Research (34 papers), Glycogen Storage Diseases and Myoclonus (14 papers) and Child Nutrition and Feeding Issues (11 papers). Alaa Hamed is often cited by papers focused on Lysosomal Storage Disorders Research (34 papers), Glycogen Storage Diseases and Myoclonus (14 papers) and Child Nutrition and Feeding Issues (11 papers). Alaa Hamed collaborates with scholars based in United States, France and Germany. Alaa Hamed's co-authors include R. K. Chandra, Luba Nalysnyk, Philip Rotella, Jason C. Simeone, Neal J. Weinreb, Steve Kanters, Jeroen P. Jansen, Andrew Stewart, Benedikt Schoser and António Toscano and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Journal of Clinical Epidemiology.

In The Last Decade

Alaa Hamed

41 papers receiving 587 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alaa Hamed United States	10	409	175	123	109	93	44	616
Iva Lloyd United Kingdom	13	151 0.4×	66 0.4×	78 0.6×	30 0.3×	53 0.6×	40	574
William Benko United States	12	356 0.9×	66 0.4×	124 1.0×	8 0.1×	206 2.2×	12	511
Serena Gasperini Italy	16	443 1.1×	282 1.6×	146 1.2×	72 0.7×	77 0.8×	64	880
Marion M. Brands Netherlands	11	271 0.7×	86 0.5×	119 1.0×	57 0.5×	47 0.5×	34	438
Machtelt G. Bouwman Netherlands	9	500 1.2×	147 0.8×	259 2.1×	18 0.2×	148 1.6×	10	580
Taiane Alves Vieira Brazil	10	373 0.9×	152 0.9×	178 1.4×	44 0.4×	62 0.7×	19	444
Jackie Imrie United Kingdom	15	529 1.3×	86 0.5×	106 0.9×	164 1.5×	44 0.5×	22	773
Amy White United States	11	204 0.5×	74 0.4×	65 0.5×	41 0.4×	27 0.3×	39	503
Loren Peña United States	11	170 0.4×	105 0.6×	23 0.2×	53 0.5×	17 0.2×	25	601
Barbara Martinelli Brazil	11	124 0.3×	74 0.4×	133 1.1×	24 0.2×	34 0.4×	15	336

Countries citing papers authored by Alaa Hamed

Since Specialization

Citations

This map shows the geographic impact of Alaa Hamed's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alaa Hamed with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alaa Hamed more than expected).

Fields of papers citing papers by Alaa Hamed

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alaa Hamed. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alaa Hamed. The network helps show where Alaa Hamed may publish in the future.

Co-authorship network of co-authors of Alaa Hamed

This figure shows the co-authorship network connecting the top 25 collaborators of Alaa Hamed. A scholar is included among the top collaborators of Alaa Hamed based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alaa Hamed. Alaa Hamed is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schiffmann, Raphael, James Turnbull, Ruth Pulikottil-Jacob, et al.. (2025). Gaucher disease type 3 from infancy through adulthood: a conceptual model of signs, symptoms, and impacts associated with ataxia and cognitive impairment. Orphanet Journal of Rare Diseases. 20(1). 171–171. 1 indexed citations

Roberts, Mark, Irina Proskorovsky, Patricia Guyot, et al.. (2025). An Indirect Treatment Comparison of Avalglucosidase Alfa versus Cipaglucosidase Alfa Plus Miglustat in Patients with Late-Onset Pompe Disease. Advances in Therapy. 42(11). 5578–5599.

Hamed, Alaa, et al.. (2024). Successful management of acute type A aortic dissection in the third trimester of pregnancy: A case report. Case Reports in Women s Health. 45. e00678–e00678.

Boentert, Matthias, Kenneth I. Berger, Jordi Díaz‐Manera, et al.. (2024). Applying the win ratio method in clinical trials of orphan drugs: an analysis of data from the COMET trial of avalglucosidase alfa in patients with late-onset Pompe disease. Orphanet Journal of Rare Diseases. 19(1). 14–14. 2 indexed citations

Schiffmann, Raphael, Eugen Mengel, Mary Wallace, et al.. (2024). Qualitative Study of the Patient Experience with Venglustat for Gaucher Disease Type 3 in a Phase 2 Open-Label, Multicenter, Multinational Study (LEAP). Advances in Therapy. 41(7). 2907–2923. 7 indexed citations

Minini, Pascal, Florian Eichler, Christopher D. Stephen, et al.. (2024). Clinical outcome assessments of disease burden and progression in late-onset GM2 gangliosidoses. Molecular Genetics and Metabolism. 142(3). 108512–108512. 1 indexed citations

Roberts, Mark, Irina Proskorovsky, Patricia Guyot, et al.. (2023). CO122 Late-Onset Pompe Disease (LOPD) Patients Treated with Avalglucosidase Alfa Show Favorable Results Compared to Cipaglucosidase Alfa Plus Miglustat: Indirect Treatment Comparison. Value in Health. 26(6). S37–S38. 1 indexed citations

Dimachkie, Mazen M., Priya S. Kishnani, Cristina Ivanescu, et al.. (2023). Measurement Properties of 2 Novel PROs, the Pompe Disease Symptom Scale and Pompe Disease Impact Scale, in the COMET Study. Neurology Clinical Practice. 13(5). e200181–e200181. 6 indexed citations

Hamed, Alaa, et al.. (2023). The epidemiology of electronic cigarette smoking among university students in the West Bank: Practice, motivation, and dependence of a new emerging hazard. SHILAP Revista de lepidopterología. 5(October). 1–8. 4 indexed citations

10.

Toscano, António, Jérôme Msihid, Nadine A. M. E. van der Beek, et al.. (2023). Effect of avalglucosidase alfa on disease-specific and general patient-reported outcomes in treatment-naïve adults with late-onset Pompe disease compared with alglucosidase alfa: Meaningful change analyses from the Phase 3 COMET trial. Molecular Genetics and Metabolism. 141(2). 108121–108121. 9 indexed citations

11.

Pulikottil-Jacob, Ruth, et al.. (2020). Patient and caregiver perspectives on burden of disease manifestations in late-onset Tay-Sachs and Sandhoff diseases. Orphanet Journal of Rare Diseases. 15(1). 92–92. 6 indexed citations

12.

Hilz, Max J., Pronabesh DasMahapatra, Qin Fan, et al.. (2020). PRO100 EVALUATION OF TREATMENT PATTERNS OF FABRY DISEASE UTILIZING MEDICAL CLAIMS ANALYSES OF A GERMAN SICKNESS FUND DATABASE. Value in Health. 23. S347–S347. 1 indexed citations

13.

Berger, Kenneth I., Steve Kanters, Jeroen P. Jansen, et al.. (2019). Forced vital capacity and cross-domain late-onset Pompe disease outcomes: an individual patient-level data meta-analysis. Journal of Neurology. 266(9). 2312–2321. 7 indexed citations

14.

Hamed, Alaa, et al.. (2019). Mobility assessment using wearable technology in patients with late-onset Pompe disease. npj Digital Medicine. 2(1). 70–70. 11 indexed citations

15.

Swinburn, Paul, et al.. (2018). A health state utility valuation study to assess the impact of treatment mode of administration in Gaucher disease. Orphanet Journal of Rare Diseases. 13(1). 159–159. 7 indexed citations

16.

Ganz, Michael L., et al.. (2017). A new framework for evaluating the health impacts of treatment for Gaucher disease type 1. Orphanet Journal of Rare Diseases. 12(1). 38–38. 4 indexed citations

17.

Schoser, Benedikt, Andrew Stewart, Steve Kanters, et al.. (2016). Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. Journal of Neurology. 264(4). 621–630. 155 indexed citations

18.

Nalysnyk, Luba, et al.. (2015). Health State Utilities for Gaucher Disease Type 1. Value in Health. 18(7). A672–A673. 1 indexed citations

19.

Nalysnyk, Luba, et al.. (2014). A Comprehensive Literature Review of the Burden of Gaucher Disease. Value in Health. 17(7). A391–A391. 3 indexed citations

20.

Ren, Xiangyu, et al.. (2004). Initiation of atypical antipsychotic agents and health outcomes in patients with schizophrenia. Journal of Clinical Pharmacy and Therapeutics. 29(5). 471–481. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact